Literature DB >> 21527845

Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria.

Kheng-Choon Lim1, Pierce Kah-Hoe Chow, John C Allen, Ghim-Song Chia, Miaoshan Lim, Peng-Chung Cheow, Alexander Y F Chung, London L P Ooi, Say-Beng Tan.   

Abstract

OBJECTIVE: To compare microvascular invasion (McVI) with parameters defined by the Milan criteria in predicting tumor recurrence and overall survival (OS) in patients with surgical resection (SR) for hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: Although the Milan criteria is discriminatory for selecting patients with good outcomes in liver transplantation and SR for HCC, it neither adequately predict tumor recurrence nor explain differences in survival for patients with good liver function. McVI is a strong indicator of intrahepatic metastasis in HCC, but its relative significance for predicting clinical outcomes compared to the Milan criteria is unclear.
METHODS: Patients undergoing SR with curative intent from January 2000 to March 2009 at the Singapore General Hospital were followed up for long-term outcomes till January 1, 2010. They were stratified first by the Milan criteria and then by the presence of McVI and compared relative to OS.
RESULTS: Altogether, 454 of the 515 patients received curative SR. There were stratified into 4 groups (Milan+, McVI-), (Milan+, McVI+), (Milan-, McVI-), and (Milan-, McVI+). All pair-wise comparisons between groups relative to OS were significant except (Milan+, McVI-) (OS, 90%, 73%, and 60% at 1, 3, and 5 years) with (Milan-, McVI-) (OS, 86%, 71%, and 61% at 1, 3, 5 years) and (Milan+, McVI+) with (Milan-, McVI+). Multivariate Cox regression analysis showed that McVI was predictive of OS, after which Milan status did not add additional discriminative information.
CONCLUSIONS: McVI is a better predictor of tumor recurrence and OS than the Milan criteria after SR for HCC. Assessment of McVI should aid in patient selection for adjuvant treatments to improve outcomes after SR.

Entities:  

Mesh:

Year:  2011        PMID: 21527845     DOI: 10.1097/SLA.0b013e31821ad884

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  159 in total

1.  Microvascular invasion in hepatocellular carcinoma.

Authors:  Emre Ünal; İlkay Sedakat İdilman; Deniz Akata; Mustafa Nasuh Özmen; Muşturay Karçaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2016 Mar-Apr       Impact factor: 2.630

2.  A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC.

Authors:  Xia Sheng; Yuan Ji; Guo-Ping Ren; Chang-Li Lu; Jing-Ping Yun; Li-Hong Chen; Bin Meng; Li-Juan Qu; Guang-Jie Duan; Qing Sun; Xin-Qing Ye; Shan-Shan Li; Jing Yang; Bing Liao; Zhan-Bo Wang; Jian-Hua Zhou; Yu Sun; Xue-Shan Qiu; Lei Wang; Zeng-Shan Li; Jun Chen; Chun-Yan Xia; Song He; Chuan-Ying Li; En-Wei Xu; Jing-Shu Geng; Chao Pan; Dong Kuang; Rong Qin; Hong-Wei Guan; Zhan-Dong Wang; Li-Xing Li; Xi Zhang; Han Wang; Qian Zhao; Bo Wei; Wu-Jian Zhang; Shao-Ping Ling; Xiang Du; Wen-Ming Cong
Journal:  Hepatol Int       Date:  2020-12-28       Impact factor: 6.047

3.  An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study.

Authors:  Xiu-Ping Zhang; Kang Wang; Xu-Biao Wei; Le-Qun Li; Hui-Chuan Sun; Tian-Fu Wen; Zong-Tao Chai; Zhen-Hua Chen; Jie Shi; Wei-Xing Guo; Dong Xie; Wen-Ming Cong; Meng-Chao Wu; Wan Yee Lau; Shu-Qun Cheng
Journal:  Oncologist       Date:  2019-05-28

4.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

5.  The Impact of Tumor Differentiation on the Prognosis of HBV-Associated Solitary Hepatocellular Carcinoma Following Hepatectomy: A Propensity Score Matching Analysis.

Authors:  Junyi Shen; Jiaye Liu; Chuan Li; Tianfu Wen; Lvnan Yan; Jiayin Yang
Journal:  Dig Dis Sci       Date:  2018-05-07       Impact factor: 3.199

6.  Microvascular infiltration has limited clinical value for treatment and prognosis in hepatocellular carcinoma.

Authors:  Nazario Portolani; Gian Luca Baiocchi; Sarah Molfino; Anna Benetti; Federico Gheza; Stefano Maria Giulini
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

7.  Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma.

Authors:  Brian K P Goh; Pierce K H Chow; Jin-Yao Teo; Jen-San Wong; Chung-Yip Chan; Peng-Chung Cheow; Alexander Y F Chung; London L P J Ooi
Journal:  J Gastrointest Surg       Date:  2014-05-23       Impact factor: 3.452

8.  Characteristics of Early Recurrence After Curative Liver Resection for Solitary Hepatocellular Carcinoma.

Authors:  Sung-Mi Jung; Jong Man Kim; Gyu-Seong Choi; Choon Hyuck David Kwon; Nam-Joon Yi; Kwang-Woong Lee; Kyung Suk Suh; Jae-Won Joh
Journal:  J Gastrointest Surg       Date:  2018-09-13       Impact factor: 3.452

Review 9.  Artificial intelligence in assessment of hepatocellular carcinoma treatment response.

Authors:  Bradley Spieler; Carl Sabottke; Ahmed W Moawad; Ahmed M Gabr; Mustafa R Bashir; Richard Kinh Gian Do; Vahid Yaghmai; Radu Rozenberg; Marielia Gerena; Joseph Yacoub; Khaled M Elsayes
Journal:  Abdom Radiol (NY)       Date:  2021-03-31

10.  Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.

Authors:  Zheng Li; Zhengqing Lei; Yong Xia; Jun Li; Kui Wang; Han Zhang; Xuying Wan; Tian Yang; Weiping Zhou; Mengchao Wu; Timothy M Pawlik; Wan Yee Lau; Feng Shen
Journal:  JAMA Surg       Date:  2018-10-17       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.